title: Radiation dose in non-small cell lung cancer: too much of a good thing?
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Dilling
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D000068818:Cetuximab; D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D019583:Dose Fractionation, Radiation; D061847:Hospitals, High-Volume; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D017239:Paclitaxel / Q000008:administration & dosage; D011788:Quality of Life; D011832:Radiation Injuries / Q000453:epidemiology; D011879:Radiotherapy Dosage; D019233:Retreatment / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D017239:Paclitaxel; D000068818:Cetuximab